Abstract:Previous work led to the rational design, synthesis and testing of novel antifungal triazole analogues bearing alkynyl-methoxyl side chains. Tests of in vitro antifungal activity showed Candida albicans SC5314 and Candida glabrata 537 gave MIC values of ≤0.125 μg/mL for most of the compounds. Among these, compounds 16, 18, and 29 displayed broad-spectrum antifungal activity against seven human pathogenic fungal species, two fluconazole-resistant C. albicans isolates and two multi-drug resistant Candida auris isolates. Moreover, 0.5 μg/mL of 16, 18, and 29 was more effective than 2 μg/mL of fluconazole at inhibiting fungal growth of the strains tested. The most active compound (16) completely inhibited the growth of C. albicans SC5314 at 16 μg/mL for 24 h, affected biofilm formation and destroyed the mature biofilm at 64 μg/mL. Several Saccharomyces cerevisiae strains, overexpressing recombinant Cyp51s or drug efflux pumps, indicated 16, 18, and 29 targeted Cyp51 without being significantly affected by a common active site mutation, but were susceptible to target overexpression and efflux by both MFS and ABC transporters. GC-MS analysis demonstrated that 16, 18, and 29 interfered with the C. albicans ergosterol biosynthesis pathway by inhibition at Cyp51. Molecular docking studies elucidated the binding modes of 18 with Cyp51. The compounds showed low cytotoxicity, low hemolytic activity and favorable ADMT properties. Importantly, compound 16 showed potent in vivo antifungal efficacy in the G. mellonella infection model. Taken together, this study presents more effective, broad-spectrum, low toxicity triazole analogues that can contribute to the development of novel antifungal agents and help overcome antifungal resistance.

Structure-Based Optimization of Novel Sterol 24-C-Methyltransferase Inhibitors for the Treatment of Candida albicans Infections

Characterization of an Allosteric Inhibitor of Fungal-Specific C-24 Sterol Methyltransferase to Treat Candida Albicans Infections

Design, Synthesis and Bioactivity Evaluation of Novel Arylalkene-Amide Derivatives As Dual-Target Antifungal Inhibitors

Structure-based design, synthesis, and antifungal activity of new triazole derivatives.

Structure-based de novo design, synthesis, and biological evaluation of non-azole inhibitors specific for lanosterol 14alpha-demethylase of fungi.

Design, synthesis, and antifungal activity of novel conformationally restricted triazole derivatives.

Potent arylamide derivatives as dual-target antifungal agents: Design, synthesis, biological evaluation, and molecular docking studies

Design, Synthesis, and Antifungal Activities of Novel 1H-Triazole Derivatives Based on the Structure of the Active Site of Fungal Lanosterol 14α-Demethylase (CYP51)

Synthesis, in Vitro Evaluation and Molecular Docking Studies of New Triazole Derivatives As Antifungal Agents.

Novel Aryl Alkamidazole Derivatives as Multifunctional Antifungal Inhibitors: Design, Synthesis, and Biological Evaluation.

Design, Synthesis and Molecular Docking Studies of Novel Triazole Antifungal Compounds

Synthesis and antifungal evaluation of novel triazole derivatives bearing a pyrazole-methoxyl moiety

Design, synthesis, antifungal evaluation, and molecular docking of novel 1,2,4-triazole derivatives containing oxime ether and cyclopropyl moieties as potential sterol demethylase inhibitors

Structure-based Virtual Screening and ADME/T-based Prediction Analysis for the Discovery of Novel Antifungal CYP51 Inhibitors.

Design, Synthesis, Evaluation and Optimization of Novel Azole Analogues As Potent Antifungal Agents

Design, synthesis, and antifungal activities of novel 1H-triazole derivatives based on the structure of the active site of fungal lanosterol 14 alpha-demethylase (CYP51).

Design, Synthesis, and Biological Evaluation of Dual-Target COX-2/CYP51 Inhibitors for the Treatment of Fungal Infectious Diseases.

Novel antifungal triazoles with alkynyl-methoxyl side chains: Design, synthesis, and biological activity evaluation.

Molecular Docking, Design, Synthesis and Antifungal Activity Study of Novel Triazole Derivatives Containing the 1,2,3-Triazole Group

2-Amino-nonyl-6-methoxyl-tetralin Muriate Inhibits Sterol C-14 Reductase in the Ergosterol Biosynthetic Pathway

Design, synthesis, and evaluation of novel tetrazoles featuring isoxazole moiety as highly selective antifungal agents